Title A split face study on the effect of an anti-acne product containing fermentation products of Enterococcus faecalis CBT SL-5 on skin microbiome modification and acne improvement
Author Hye Sung Han1, Sun Hye Shin1, Bo-Yun Choi2, Nayeon Koo1, Sanghyun Lim3, Dooheon Son3, Myung Jun Chung3, Kui Young Park1*, and Woo Jun Sul2*
Address 1Department of Dermatology, Chung-Ang University College of Medicine, Seoul 06974, Republic of Korea, 2Department of Systems Biotechnology, Chung-Ang University, Anseong 17546, Republic of Korea, 3R&D Center, Cell Biotech, Co., Ltd., Gimpo 10003, Republic of Korea
Bibliography Journal of Microbiology, 60(5),488–495, 2022,
DOI 10.1007/s12275-022-1520-6
Key Words acne vulgaris, Enterococcus faecalis, skin microbiome, dysbiosis
Abstract Antibiotic-resistant Cutibacterium acnes and dysbiosis of the skin microbiome are of increasing concern in acne treatment. Enterococcus faecalis, a widely used probiotic, has shown benefits for acne treatment by exerting antimicrobial activity against C. acnes. Therefore, this study aimed to investigate the efficacy and safety of an E. faecalis CBT SL-5-extract-containing lotion in patients with mild-to-moderate acne. Twenty patients were enrolled in this randomized, placebo-controlled, split-face comparative study. Patients were treated with E. faecalis lotion on one side of the face and a vehicle lotion on the other side for 4 weeks. The efficacy outcome measures included improvement in the investigators’ assessment of acne severity, patient satisfaction, changes in skin parameters and diversity of the skin microbiome. The investigators’ assessment score was significantly improved on the test side compared to the control side, after 2 weeks (p = 0.009) and 6 weeks (p < 0.0005). However, TEWL and skin hydration were not significantly different between the two groups. The phylogenetic diversity of the skin microbiota decreased over time in the skin samples of test side. In conclusion, E. faecalis CBT SL-5 extract can be a feasible and well-tolerated option for improving acne severity and skin microbiome dysbiosis in mild-to-moderate acne patients.